Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of rebamipide 100 mg tablets in healthy Thai volunteers
TCTR20260910002Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rebamipide (2 arms), sponsored by International Bio Service. Primary endpoints: Maximum observed plasma concentration (Cmax), Area under the plasma concentration-time curve from zero to last measurable concentration (AUC0-tlast) and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
rebamipide
Beyond the preview
Go deeper on TCTR20260910002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260910002.